top of page

FDA Grants Breakthrough Therapy Designation for Lucentis in Diabetic Retinopathy

December 15, 2014

Based on the phase 3 RISE/RIDE trials, which show meaningful improvements in diabetic retinopathy in Lucentis-treated patients compared to sham-treated patients over 2 years, the FDA has granted Lucentis breakthrough therapy designation.


bottom of page